3 active not recruiting, 2 not yet recruiting, 1 recruiting, 1 terminated. 5 Phase 2, 3 Phase 1, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Active not recruiting 3, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 2, Not yet recruiting 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Prosthetic Joint Infections of Hip: new trials by email Literature Review of Prosthetic Joint Infections of Hip trials Research Report on Prosthetic Joint Infections of Hip
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antibiotic-coated Braided Suture Study VICRYL™ Plus (Coated VICRYL™ Plus Antibacterial), Polydioxanone (PDS™ II ) Sterile Synthetic Absorbable Surgical Suture-Monofilament - Prosthetic Joint Infection, Debridement With Prosthesis Retention | Not applicable | Not yet recruiting | University of Miami | 142 | 2026-11-01 | 2026-07-08 |
| Bacteriophage Therapy for Staphylococcus Lugdunensis Prosthetic Joint Infection Five phage anti-Staphylococcus aureus bacteriophage cocktail - Prosthetic Joint Infections of Hip, Bacteriophage Therapy | Phase 1 / Phase 2 | Not yet recruiting | University of Calgary | 1 | 2026-03-01 | 2026-03-10 |
| Study to Evaluate the Efficacy and Safety of TRL1068 for the Treatment of Prosthetic Joint Infection TRL1068 (calpurbatug), a human monoclonal antibody, DAIR - Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee | Phase 2 | Active not recruiting | Trellis Bioscience LLC | 60 | 2025-04-08 | 2026-05-07 |
| Bacteriophage Therapy for Morganella Morganii Prosthetic Joint Infection phage therapy - Prosthetic Joint Infections of Hip | Phase 1 / Phase 2 | Active not recruiting | University of Calgary | 1 | 2025-03-26 | 2025-06-12 |
| ROADMAP Clinical Trial Debridement and Implant Retention (DAIR), Antibiotic Choice, Antibiotic duration Part A - Single stage revision - Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee | Phase 4 | Recruiting | University of Newcastle, Australia | 2500 | 2025-03-24 | 2026-07-27 |
| Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection Phage therapy - Prosthetic Joint Infections of Hip, Staphylococcus Aureus Infection | Phase 1 / Phase 2 | Active not recruiting | University of Calgary | 1 | 2024-11-20 | 2025-06-11 |
| Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection CEM-102, IV or Oral standard of care antibiotics, Rifampin - Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee | Phase 2 | Terminated | Arrevus Inc. | 14 | 2012-12-01 | 2019-04-19 |
Bacterial Infections (1) · Bacterial Infections and Mycoses (1) · Gram-Positive Bacterial Infections (1) · Infections (1)
Debridement (2) · Phage Therapy (2) · Anti-Bacterial Agents (1) · Cefazolin (1) · Ceftaroline (1) · Ceftriaxone (1) · Ciprofloxacin (1) · Daptomycin (1) · Fusidic Acid (1) · Levofloxacin (1) · Linezolid (1) · Nafcillin (1) · Oxacillin (1) · Rifampin (1) · TRL1068 (1)
University of Calgary (3) · Arrevus Inc. (1) · Trellis Bioscience LLC (1) · University of Miami (1) · University of Newcastle, Australia (1)
Canada (3) · United States (3) · Australia (1) · New Zealand (1)
Colin McNamara, MD (1) · Laurens Manning, Co-chief Investigator, infectious diseases Specialist (1)